Glenmark finds molecule for treating blood cancer
Glenmark Pharmaceuticals on Thursday said it has discovered a new drug molecule which can treat blood and lymph cancer, besides inflammatory disorders.
By ET Bureau | Updated:
NEW DELHI: Glenmark Pharmaceuticals on Thursday said it has discovered a new drug molecule which can treat blood and lymph cancer, besides inflammatory disorders.
The novel biological entity, (NBE) 'GBR 401', was discovered by the company's Switzerland-based arm Glenmark Pharmaceuticals SA, the company said in a statement.
"Glenmark will file for phase-I trials in the fourth quarter of FY2011-12," it added. The disease areas primarily targeted by GBR 401 are lymphoma and leukaemia of B-cell origin. Leukaemia is a type of cancer of the blood or bone marrow and lymphoma is a form of cancer in the lymphatic cells of the immune system. GBR 401 also holds the potential to treat disorders such as rheumatoid arthritis, it added.
The novel biological entity, (NBE) 'GBR 401', was discovered by the company's Switzerland-based arm Glenmark Pharmaceuticals SA, the company said in a statement.
"Glenmark will file for phase-I trials in the fourth quarter of FY2011-12," it added. The disease areas primarily targeted by GBR 401 are lymphoma and leukaemia of B-cell origin. Leukaemia is a type of cancer of the blood or bone marrow and lymphoma is a form of cancer in the lymphatic cells of the immune system. GBR 401 also holds the potential to treat disorders such as rheumatoid arthritis, it added.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
